Posts by Sandra Ansanay-Alex
Source Challenge – Défi Source
The launch event of the Défi Source, run by H4-Hands on Human Health Hub, is taking place on 28 October at Beaulieu Lausanne The Source Challenge brings together healthcare professionals, students, researchers, entrepreneurs and experts to tackle a shared challenge: devising solutions that will meet the healthcare needs of the future. The launch event will take place at…
Read MoreWorld Health Summit
The World Health Summit is taking place on 11 – 13 October 2026 in Berlin, Germany Join policymakers, scientists, health professionals, civil society representatives, and private-sector leaders from around the world to explore how innovation can build resilient, equitable, and future-ready health systems. More than 400 speakers from across sectors and regions will explore, in…
Read MoreFIT Awards 5 New Tech Grants to CHUV and EPFL Projects
The Foundation for Technological Innovation (FIT) has announced new Tech Grants supporting five Swiss Health Valley projects, worth CHF 100,000 each, to promising projects from the canton of Vaud. Three grants go to Chorus Tre, HeteroSight and SixtineAI, all originating from CHUV, while two others support Cookd Labs and Endobotica, born at EPFL. Chorus Tre…
Read MoreISREC Foundation Awards CHF 3.4 Million to Seven Cancer Research Teams
Cancer research thrives at the intersection of the laboratory and the clinic — where fundamental discoveries meet the realities of patient care. The TANDEM grants, awarded by the ISREC Foundation, are built precisely for that intersection. TANDEM projects are collaborative research programmes that bring together basic and clinical research in oncology. Scientists and physicians work…
Read MoreNewBiologix and Synastra Biotechnology Partner to Advance Stable rAAV Manufacturing for Duchenne Muscular Dystrophy Gene Therapy
NewBiologix S.A., a Swiss biotechnology company pioneering stable cell line technologies for recombinant adeno-associated virus (rAAV) manufacturing, announced an agreement with Synastra Biotechnology Inc. to develop a stable producer cell line for Synastra’s investigational Duchenne muscular dystrophy (DMD) gene therapy programme. Synastra is a Türkiye-based gene therapy company established through a collaboration between Üsküdar University and Unifon-Biotech GSYF Venture…
Read MoreLa Tour Hospital Partners with Evidone
La Tour Hospital announces the launch of a pilot partnership with Evidone SA, a Swiss Health Valley healthcare technology company that develops computer vision and artificial intelligence solutions for hospital sterilisation departments and operating theatres. The aim of this partnership is to deploy and evaluate Evidone SA’s technology in real-world clinical settings, with a view…
Read MoreFluoSphera Partners with Debiopharm and Leica Microsystems
A new meaningful partnership in the Swiss Health Valley! FluoSphera licenses Debiopharm’s AbYlink™ Technology for 3D antibody characterization while leveraging Leica Microsystems Viventis deep imaging capabilities. The New license agreement enables an integrated workflow combining antibody labeling, human-relevant 3D testing and quantitative imaging for antibody-based therapeutics Debiopharm (Debiopharm Research & Manufacturing), a privately-owned, Swiss-based biopharmaceutical…
Read MoreBruker expands its collaboration with Atinary and makes a minority investment
Bruker Corporation (NASDAQ:BRKR) announced that it is expanding its strategic collaboration with Atinary Technologies Inc., and acquiring a minority stake in the Lausanne-based company. The financial terms of the deal were not disclosed, according to the press release. This collaboration aims to integrate Chemspeed’s laboratory automation platforms, Bruker’s analytical instruments and SciY’s scientific software into…
Read MoreSwiss Gender Medicine Symposium
The Swiss Gender Medicine Symposium is taking place on 26 and 27 October 2026 at the Kursaal Bern Gender medicine has long since answered the question of whether biological sex and gender play a role. The evidence is there. What remains is the more difficult task: translating this knowledge into clinical practice, research structures, and…
Read MoreAlcon Halts Intraocular Lens Programmes After $402 Million Writedown
Alcon, the Geneva-based global leader in eye care, announced on Monday evening that it is discontinuing its intraocular lens (IOL) programmes, technology it acquired through the 2019 purchase of PowerVision for $285 million. These lenses were primarily designed for use in cataract surgery, replacing the eye’s clouded natural lens. Alcon has its global headquarters in…
Read More